APRIL (AbatacePt in RA-ILD)
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
APRIL (AbatacePt in RA-ILD) is a clinical trial[1].
Key Facts
- APRIL (AbatacePt in RA-ILD) is in the country of United Kingdom[2].
- APRIL (AbatacePt in RA-ILD)'s instance of is recorded as clinical trial[3].
- APRIL (AbatacePt in RA-ILD)'s start time is recorded as +2018-06-26T00:00:00Z[4].
- APRIL (AbatacePt in RA-ILD)'s end time is recorded as +2020-03-01T00:00:00Z[5].
- APRIL (AbatacePt in RA-ILD)'s contributor to the creative work or subject is recorded as Bristol-Myers Squibb[6].
- APRIL (AbatacePt in RA-ILD)'s main subject is recorded as arthritis[7].
- APRIL (AbatacePt in RA-ILD)'s number of participants is recorded as {'unit': '1', 'amount': '+30'}[8].
- APRIL (AbatacePt in RA-ILD)'s title is recorded as Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial[9].
- APRIL (AbatacePt in RA-ILD)'s short name is recorded as APRIL[10].
- APRIL (AbatacePt in RA-ILD)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[11].
- APRIL (AbatacePt in RA-ILD)'s ClinicalTrials.gov ID is recorded as NCT03084419[12].
- APRIL (AbatacePt in RA-ILD)'s research intervention is recorded as abatacept[13].
- APRIL (AbatacePt in RA-ILD)'s clinical trial phase is recorded as phase II clinical trial[14].
- APRIL (AbatacePt in RA-ILD)'s research site is recorded as University of Cambridge[15].
- APRIL (AbatacePt in RA-ILD)'s study type is recorded as interventional study[16].